6 active not recruiting, 3 recruiting, 1 not yet recruiting, 1 withdrawn. 5 Phase 2, 3 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 4, Withdrawn 1 |
| Not applicable | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Oligometastatic Prostate Carcinoma: new trials by email Literature Review of Oligometastatic Prostate Carcinoma trials Research Report on Oligometastatic Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Addressing Health Literacy With a Tailored Survivorship Care Plan Educational Intervention, Interview, Questionnaire Administration - Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Not applicable | Recruiting | Emory University | 150 | 2025-11-07 | 2026-09-30 |
| Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan - Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Not applicable | Recruiting | Mayo Clinic | 50 | 2024-06-11 | 2026-04-06 |
| Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer ADT combined with abiraterone, neoadjuvant hormone and RT - Oligometastatic Prostate Carcinoma | Not applicable | Not yet recruiting | Changhai Hospital | 200 | 2024-05-01 | 2024-02-20 |
| Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 110 | 2024-04-22 | 2026-09-25 |
| SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Phase 3 | Active not recruiting | Mayo Clinic | 118 | 2024-04-04 | 2026-09-17 |
| [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC) - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 142 | 2024-04-03 | 2026-10-06 |
| OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate Oligometastatic Prostate Carcinoma | Recruiting | Istituto Oncologico Veneto IRCCS | 150 | 2023-01-23 | 2025-04-17 | |
| 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 93 | 2022-09-02 | 2026-05-26 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Apalutamide, Degarelix, Leuprolide Acetate - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-11-24 | 2021-01-20 | |
| A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment - Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 84 | 2020-01-06 | 2026-10-20 |
Prostatic Neoplasms (8) · Genital Neoplasms, Male (1) · Urogenital Neoplasms (1)
Genital Diseases (8) · Genital Diseases, Male (8) · Male Urogenital Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Prostatic Diseases (8) · Urogenital Diseases (8) · Genital Neoplasms, Male (7) · Urogenital Neoplasms (7) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Radiation (3) · Radiosurgery (3) · Radiotherapy (2) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Early Intervention, Educational (1) · Educational Status (1) · Glutamate Carboxypeptidase II (1) · Gonadotropin-Releasing Hormone (1) · Interviews as Topic (1) · Leuprolide (1) · Methods (1) · Palliative Care (1)
Mayo Clinic (4) · Changhai Hospital (1) · Eli Lilly and Company (1) · Emory University (1) · Istituto Oncologico Veneto IRCCS (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · NRG Oncology (1)
United States (8) · Canada (2) · China (1) · Italy (1)
Amar Kishan, MD (1) · Brian J. Davis, M.D. (1) · Bridget F Koontz (1) · Carlos E. Vargas, M.D. (1) · Carlos E. Vargas, MD (1) · Eleni Efstathiou (1) · Ram A. Pathak, MD (1) · Viraj Master, MD, PhD, FACS (1)
P30CA138292 (1), U10CA180868 (1)